Key Investor Information This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Global X Genomics & Biotechnology UCITS ETF (the "Fund"), A sub-fund of Global X ETFs ICAV (the "ICAV") USD Accumulating Share Class, IE00BM8R0N95 The Fund is managed by Global X Management Company (Europe) Limited (the "Manager").

Objectives and Investment Policy The Fund’s investment objective is to generate returns that closely

namely, total return “unfunded” OTC swaps and exchange-traded equity correspond, before fees and expenses, generally to the price and yieldfutures for investment purposes. performance of the Solactive Genomics v2 Index (the “Index”).

The Fund may enter into securities lending transactions, investing in The Fund is passively managed. The Fund will aim to achieve its

repurchase and reverse repurchase transactions and collective investment objective by attempting to replicate the performance of theinvestment schemes, for the purposes of efficient portfolio management Index by investing primarily in a portfolio of equity securities that as far as

only. possible and practicable consists of the component securities of the Index in similar proportions to their weightings in the Index and in american

The Fund’s base currency is USD. depositary receipts (“ADRs”) and global depositary receipts (“GDRs”)

For Accumulating Shares, income will be automatically reinvested in the based on the securities in the Index. Fund and reflected in the NAV per share. The Index is designed to provide exposure to exchange-listed companiesInvestors can buy and sell shares of the Fund on each business day. that are positioned to benefit from further advances in the field of genomic

Business day means a day on which the New York Stock Exchange and science and biotechnology, as well as applications thereof (collectively, “Genomics & Biotechnology Companies”), as defined by Solactive AG London Stock Exchange are open for normal business. (the “Index Provider”).

For more information about the investment policy and strategy of Genomic and Biotechnology Companies include those involved in the the Fund, please refer to the sections entitled “Investment following business activities (i) genomic editing, (ii) genomic sequencing,

Objective” and “Investment Policy” in the Fund’s Supplement. (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics. In order to be eligible for inclusion in the Index, a company shall generate revenues from relevant activities. (i) Pure-Play which derives at least 50% of revenues from genomics activities which means a process that involves exploring and understanding the structure, function, and evolution of genomes (“Genomics Activities”). (ii) Pre-Revenue which has primary business operations in Genomics Activities but does not currently generate revenues. (iii) Diversified which derives revenues from Genomics Activities but less than 50%. When not possible or practicable to continue to hold all of the component securities of the Index, the Fund may invest in depositary receipts relating either to components securities of the Index or to equity securities of the type referred to above; and financial derivative instruments (“FDIs”),

Risk and Reward Profile

Lower Risk

Higher Riskin Genomic and Biotechnology Companies. The lack of diversification

across the Fund’s portfolio may increase the losses suffered by the Fund

if the Genomic and Biotechnology Companies as a group were to suffer a

Typically lower rewardsTypically higher rewards downturn. Furthermore, these companies may adversely be affect by

factors such as, but not limited to, new governmental regulations, rapid

product obsolescence, intense competition and intellectual property

1

2

3

4

5

6 7rights. These companies typically engage in significant amounts of

spending on research and development which is not guaranteed to be This indicator above is based on historical data and may not be a reliablesuccessful. indication of the future risk profile of the Fund. The risk category shown is Market Risk: The risk that the market will go down in value, with the not guaranteed and may change over time. The lowest category does not possibility that such changes will be sharp and unpredictable. mean a risk-free investment.

Operational Risk (including safekeeping of assets): The Fund and its This Fund is in risk category 7 due to the range and frequency of price

assets may experience material losses as a result of technology/system movements (i.e. the volatility) of the underlying investments referenced

failures, human error, policy breaches, and/or incorrect valuation of by the Fund which may not be a reliable indicator of the future risk profile

units. Social, political and economic developments and laws differ of the share class.

between regions. Changes in these may impact the Fund such as any

changes that may occur due to the U.K’s withdrawal from the EU The Fund offers no capital guarantee or protection.

(Brexit). The Fund may be subject to risks which are not included in theRisks associated with the ability to track an index: Transaction costs calculation of the risk-reward indicator. Key risk factors include:

and other fees and expenses to be borne by the Fund and exchange rate

factors where the underlying equities are denominated in a different Currency Risk: Some of the Fund's investments will be denominated in

currency to the Base Currency or currency of any Class of Shares are currencies other than the Fund’s base currency (USD) therefore investors

likely to affect the ability of a Fund to track the performance of the Index. may be affected by adverse movements of the denominated currency and the base currency. The Fund may attempt to use FDIs to hedge

Liquidity Risk: The Fund may invest in securities which may, due to against negative currency movements, however there is no guaranteenegative market conditions, become difficult to sell or may need to be that any attempts at hedging will be successful. You may receive

sold at an unfavourable price. This may affect the overall value of the payments in a different currency, so the final return you will get depend Fund. on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

For more information on risks, please see the sections entitled Derivatives Risk: The Fund may invest in FDIs to hedge against risk

"Risk Factors" in the ICAV's prospectus and in the Fund's and/or to increase return. There is no guarantee that the Fund’s use of

supplement to the ICAV's prospectus. derivatives for either purpose will be successful. Derivatives are subject to counterparty risk (including potential loss of instruments) and are highly sensitive to underlying price movements, interest rates and market volatility and therefore come with a greater risk. Equities Risk: The Fund may invest in equity securities which are subject to greater fluctuations than other assets. Factors which may affect the fluctuation including economic conditions, industry or company news. High volumes of trading may also see increased transaction costs. Concentration Risk: The Fund’s investments will be highly concentrated :DocID: KIID_IE00BM8R0N95_en_20260213_6_1_USD_Accumulating_Share_Cl_648892 Charges The charges you pay are used to pay the costs of running the Fund,

The entry and exit charges shown are maximum figures. In some cases you including the costs of marketing and distributing the Fund. These

might pay less - you can find this out from your financial adviser. charges reduce the potential growth of your investment. The ongoing charges figure shown here is based on the total expense ratio of the Fund that the Investment Manager has agreed to cap. The Manager One-off charges taken before or after you investgives a commitment to respect the published figure shown and to discharge any excess amounts out of its own assets for all other fees and expenses

Entry Charge

None *

over this cap which may arise.

Exit ChargeNone *

The ongoing charge figure excludes performance fees and portfolio This is the maximum that might be taken out of your money before it is

transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another collective investment invested or before the proceeds of your investment are paid out.undertaking. Charges taken from the Fund over a year:* Secondary market investors (Investors dealing on a stock exchange) may pay fees charged by their stock brokers. Such charges, if any, can be Ongoing Charges 0.50% **obtained from stock brokers. Authorised participants dealing directly with Charges taken from the fund under certain specific conditions

the Fund will pay related transaction costs related to their subscriptions and redemptions. Performance Fee

None ** To the extent the Fund undertakes securities lending, the Fund will receive 87% of the associated revenue generated from securities lending activities and the remaining 13% will be retained by the securities lending agent (representing the attendant direct and indirect operational costs and fees of the securities lending). As securities lending does not increase the costs of running the fund, this has been excluded from the ongoing charges. Please refer to the “Fees, Costs and Expenses” section of the ICAV’s Prospectus and “Fees and Expenses” section of the Supplement to the Prospectus for further detail on charges and fees for the relevant share classes.

Past Performance

30%

Past performance is not an indicator of future results. 19.3%

20%

18.9%

The past performance takes account of all charges and costs.10%

The performance of this class is calculated in US Dollar.

There is insufficient data to produce a useful indication of past0%performance for the share class.

The Fund was established in 2021.

-10% -8.6% The class launched on 2 November 2021.

-8.2%

-20% -16.0%-15.5%

-30%

-40%

-36.1%

-35.9%

2021

20222023 2024

2025USD Accumulating Share Class

Solactive Genomics v2 Index (Benchmark)Practical Information Depositary Bank: SEI Investments – Depositary and Custodial ServicesAccuracy Statement: The Manager may be held liable solely on the (Ireland) Limited

basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Further Information: Further information about the ICAV, copies of the Prospectus. Prospectus and Fund Supplement, latest annual, semi-annual reports and other practical information may be obtained free of charge from Umbrella Fund: The Fund is a sub-fund of Global X ETFs ICAV, an Irish https://www.globalxetfs.eu and at the registered office of the ICAV.collective asset-management vehicle constituted as an umbrella fund with segregated liability between sub-funds. Latest Share Prices/Net Asset Value: The latest share prices will be made available on https://www.globalxetfs.eu or by contacting the

Segregated Liability: Under Irish law the assets and liabilities of the Administrator, SEI Investments – Global Fund Services Limited.

Fund are segregated from other sub-funds within the ICAV and the assets of the Fund will not be available to satisfy the liabilities of another Remuneration Policy: Details of the remuneration policy of the Manager fund of the ICAV. are available on the Manager's website, https://www.globalxetfs.eu. A paper copy will be available free of charge from the office of the Manager

This Fund is authorised in Ireland and regulated by Central Bank of upon request.

Ireland. The Manager is authorised in Ireland and regulated by the Central Bank of Ireland. Conversion of Shares: A Shareholder may convert shares of one fund into shares of another fund or shares of a class within a fund into shares of a different class within the same fund, switching fees may apply. Notice should be given to the Directors in such form as the Directors may require. Please refer to the Prospectus for the ICAV for further details on how to exercise your right to switch. Tax Legislation: The taxation of income and capital gains of the ICAV and of the Shareholders is subject to the fiscal laws and practices of Ireland, of the countries in which the ICAV invests and of the jurisdictions in which the Shareholders are resident for tax purposes or otherwise subject to tax. Depending on your country of residence, this may impact your personal tax position. For further details, please speak to your financial adviser.This Key Investor Information is accurate as at 13/02/2026. : DocID: KIID_IE00BM8R0N95_en_20260213_6_1_USD_Accumulating_Share_Cl_648892